Lei Zhang,Yan Liu,Xiao Ting Lu,Xin Sheng Xu,Yu Xia Zhao,Xiao Ping Ji,Peng Fei Zhang,Chun Xi Liu,Meng Xiong Tang,Wen Qiang Chen,Yun Zhang.Intraplaque injection of Ad5‐CMV.p53 aggravates local inflammation and leads to plaque instability in rabbits[J]. Journal of Cellular and Molecular ...
status to to p53 in NPC. mutated majority primary of reports derived indicate (16, but there protein The but with cell p53 gene of recombinant protein expression when treated with of recombinant levels observed was expression p53 also were also observed in the NPC cell lines Ad5CMV-p53 at ...
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 2006; 24: 2052-2058.Tolcher AW, Hao D, de Bono J, Miller A, Patnaik...
a phase 2 trial of surgery with perioperative ingn 201 (ad5cmv-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx:objectivein patients with advanced squamous cell carcinoma of the head and neck (...
Ad5CMV-p53 Has Antitumor Effect in Head and Neck Cancer.Marble, Michelle
p53 ( Ad5CMVp53 )WS AnYJ HanSD ChoJW KimJM LeeSE NamkoongSJ KimJK KimYS ParkJM Yang대한산부인과학회
G1 cell cycle arrest was observed after Ad5CMV-p53 infection and the combination in both cell lines. Conclusion: In this study, we demonstrated that the combination of IR and Ad5CMV-p53 gene therapy resulted in remarkable synergistic effects in human prostate cancer cells. This combination ...
New therapeutical approaches involving p53 gene replacement appear to be very encouraging due to the key role of p53 in the cell response to DNA damage. Here, we have evaluated the effectiveness of combining wild-type p53 (wt-p53) gene reintroduction (Ad5CMV-p53) and exposure to two ...
INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy Introgen, RPR/INGN 201AdisRandDProfilesIntrogen's adenoviral p53 gene therapy [INGN 201, ADVEXIN庐] is in clinical development for the treatment of various cancers. The p53 tumour suppressor gene is deleted...